Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing

Published 22/02/2023, 14:35
© Reuters.  Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing

Benzinga -

  • Sorrento Therapeutics Inc (NASDAQ: SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners.
  • The financing will provide Sorrento with immediate liquidity to continue operating its business as usual during its chapter 11 case.
  • A hearing for final financing approval is currently set for March 29, 2023.
  • Related: Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork.
  • As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets.
  • Scilex Holding Company, majority-owned by Sorrento, is not a debtor in Sorrento's chapter 11 case. Scilex continues to operate as usual, focusing on growing revenues and offering non-opioid pain management products.
  • Latham & Watkins LLP and Jackson Walker LLP serve as legal counsel to Sorrento. M3 Partners is serving as a restructuring advisor.
  • Price Action: SRNE shares are up 10.9% at $0.44 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.